Ipswich Investment Management Co. Inc. Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Ipswich Investment Management Co. Inc. boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,579 shares of the medical research company’s stock after purchasing an additional 1,215 shares during the quarter. Ipswich Investment Management Co. Inc.’s holdings in Edwards Lifesciences were worth $1,264,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Advisors Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences by 0.3% in the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after buying an additional 117 shares in the last quarter. Apollon Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 1.0% in the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after buying an additional 119 shares in the last quarter. Geller Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 6.5% in the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after buying an additional 120 shares in the last quarter. Martin Capital Advisors LLP boosted its holdings in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after buying an additional 128 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

EW opened at $85.94 on Friday. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $51.73 billion, a PE ratio of 37.37, a P/E/G ratio of 4.26 and a beta of 1.05. The firm has a 50 day moving average of $90.15 and a two-hundred day moving average of $78.37. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period in the previous year, the firm earned $0.64 EPS. The business’s quarterly revenue was up 13.3% on a year-over-year basis. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EW. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target on the stock in a report on Friday, February 2nd. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Oppenheimer lifted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Finally, Evercore ISI lifted their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.